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OBJECTIVES We assessed the effects of long-term amlodipine administration in a diastolic heart failure
(DHF) rat model with preserved systolic function as well as the relationship between changes
in left ventricular (LV) myocardial stiffening and alterations in extracellular matrix.
BACKGROUND Although the effect of long-term administration of amlodipine has been shown to be
disappointing in patients with systolic failure, the effect is unknown in those with DHF.
METHODS Dahl salt-sensitive rats fed a high-salt diet for seven weeks were divided into three groups:
eight untreated rats (DHF group), eight rats given high-dose amlodipine (10 mg/kg/day;
HDA group) and seven rats given low-dose amlodipine (1 mg/kg/day; LDA group).
RESULTS High-dose administration of amlodipine decreased systolic blood pressure and controlled
excessive hypertrophy, without a decrease in the collagen content, and prevented the elevation
of LV end-diastolic pressure at 19 weeks. Low-dose administration of amlodipine with
subdeppressive effects did not control either hypertrophy or fibrosis; however, it prevented
myocardial stiffening and, hence, the elevation of LV end-diastolic pressure. The ratio of type
I to type III collagen messenger ribonucleic acid levels was significantly lower in both the
HDA and LDA groups than in the DHF group.
CONCLUSIONS Long-term administration of amlodipine prevented the transition to DHF both at the
depressor and subdepressor doses. Amlodipine did not decrease the collagen content, but
attenuated myocardial stiffness, with inhibition of the phenotype shift from type III to type
I collagen. Thus, amlodipine may exert beneficial effects through amelioration of collagen
remodeling in the treatment of DHF. (J Am Coll Cardiol 2001;38:1539–45) © 2001 by the
American College of Cardiology
Calcium antagonists have been used in the treatment of
hypertension or heart failure because they have vasodilating
effects, resulting in a reduction of myocardial oxygen de-
mand. However, recent clinical studies have shown that
long-term administration of short-acting calcium antago-
nists may increase the mortality of patients with heart
failure (1). Although amlodipine, as a long-acting,
dihydropyridine-based calcium antagonist, was expected to
bring more beneficial results, the Prospective Randomized
AmlodIpine Survival Evaluation II (PRAISE II) trial failed
to demonstrate its benefit in patients with nonischemic
heart failure. All of the patients studied in the PRAISE II
trial, however, had marked left ventricular (LV) systolic
dysfunction, and we may safely say that the effect of
long-term administration in patients with another type of
heart failure—diastolic heart failure (DHF) with preserved
LV systolic function—remains totally unclear. In fact, 30%
to 50% of patients with congestive heart failure (CHF) have
demonstrated LV diastolic dysfunction with preserved systolic
function, i.e., isolated DHF, and their most common under-
lying cardiovascular disease is hypertensive heart disease (2,3).
Recently, our laboratory developed a rat model of DHF
in which compensated LV hypertrophy (4) is followed by
the progression of LV fibrosis and renin-angiotensin-
system–dependent excessive hypertrophy, resulting in he-
modynamic alterations consistent with CHF (5). Left ven-
tricular myocardial stiffening is not associated with LV
dilation or systolic dysfunction, even at the end-stage of
heart failure in this model (6,7). This model was used to
study the preventive effects of long-term amlodipine admin-
istration in the transition to DHF and, if effective, to clarify
its mechanism. In studying the mechanism, we exclusively
focused on the depressor effect and effects on extracellular
matrix (ECM) regulation, because myocardial stiffening is
considered to be closely related to ECM components,
particularly collagen, in our model of DHF.
METHODS
This study conforms to the guiding principles of Osaka
University Graduate School of Medicine, with regard to
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animal care, and to the “Guide for the Care and Use of
Laboratory Animals,” published by the National Institutes
of Health, Bethesda, Maryland.
Study subjects. Laboratory chow containing 0.3% sodium
chloride was fed to weaning male Dahl-Iwai salt-sensitive
(Dahl-SS) rats (DIS/Eis, Eisai, Tokyo, Japan) until their
diet was switched to laboratory chow containing 8% sodium
chloride at seven weeks of age. The rats were randomized to
no treatment (DHF group, n  8) or treatment with a
calcium channel antagonist, amlodipine at 1 mg/kg per day
(low-dose amlodipine [LDA] group, n  7) or 10 mg/kg
per day (high-dose amlodipine [HDA] group, n  8),
courtesy of Sumitomo Pharmaceuticals Company, from
eight weeks of age. Amlodipine was given by gastric lavage
every morning. Laboratory chow containing 0.3% sodium
chloride was continuously fed to the male Dahl-SS rats, and
they comprised the age-matched control group (n  6).
Systolic blood pressure (BP) and heart rate were obtained at
7, 13, 15, 17 and 19 weeks of age, with a tail-cuff system
(BP-98A, Softron, Tokyo, Japan).
Echocardiographic and hemodynamic studies. Trans-
thoracic echocardiographic recordings were obtained at 19
weeks of age, as previously described (4). Specifically, the
rats were anesthetized with intraperitoneal administration
of ketamine hydrochloride (50 mg/kg) and xylazine hydro-
chloride (10 mg/kg), and an echocardiographic machine
equipped with a 7.5-MHz transducer (SONOS 2000,
Philips Medical Systems Corp., Best, Netherlands) was
used to make M-mode LV echocardiographic recordings at
a paper speed of 100 mm/s. Left ventricular fractional
shortening was calculated as described previously (4). Mid-
wall fractional shortening was calculated according to the
two-shell cylindrical model of Shimizu et al. (8) to avoid
overestimation of systolic function in the hypertrophied
heart, as described previously (4).
After the echocardiographic study, high-fidelity LV pres-
sure was recorded to determine LV end-diastolic pressure,
as previously described (4). The digitized LV pressure
recording was also used to calculate the time constant of
isovolumic LV pressure fall (tau), using a non-zero asymp-
tote method, as previously described (9).
Determination of myocardial stiffness constant. Simul-
taneous recordings of LV pressure and LV M-mode echo-
cardiography were obtained in all of the rats studied, and
myocardial stiffness constant (MSC) was obtained accord-
ing to the method of Sugawara et al. (7,10), as previously
described. The mean value of MSC of the septum and
posterior wall was used for statistical analysis.
Tissue sampling. After hemodynamic studies, adequate
anesthesia was achieved by additional intraperitoneal ad-
ministration of ketamine hydrochloride (50 mg/kg) and
xylazine hydrochloride (10 mg/kg). After an incision was
made in the chest, the heart was quickly harvested. The
apical site of the LV below the papillary muscle was
removed, weighed, immediately placed in liquid nitrogen
and stored at80°C for measurement of the hydroxyproline
content (6). The results were calculated as the hydroxypro-
line content per wet weight of tissue. Samples of the LV for
measurement of the amount of messenger ribonucleic acid
(mRNA) were weighed, immediately placed in liquid nitro-
gen and stored at 80°C. Samples for immunohistochem-
istry were weighed, immersed in Tissue-Tek O.C.T. com-
pound (Sakura Finetechnical Co., Tokyo, Japan) and frozen
at 80°C. The summed LV weight corrected for body
weight was determined as the LV mass index.
Immunohistochemistry. Serial cryostat transverse sections
of 5-m thickness were fixed in acetone for 10 min,
air-dried and stained by the indirect immunohistologic
method. Tissue sections were treated with 0.3% H2O2
solution for 10 min to inhibit endogenous peroxidase
activity and then incubated with blocking solution (10%
donkey serum, Rockland, Maine), followed by 2-h incuba-
tion with rabbit polyclonal rat type I collagen antiserum
(1:2,000 dilution, LSL, Tokyo, Japan) or rabbit polyclonal
rat type III collagen antiserum (1:500 dilution, Chemicon,
Temecala, California). After washing in phosphate-buffered
saline for 10 min, the sections were incubated with second-
ary donkey anti-rabbit antibody and visualized with
3-amino-9-ethyl carbazole (Zymed Laboratories, San Fran-
cisco, California) as substrate. The nuclei were stained with
hematoxylin, and the sections were viewed with a light
microscope at a magnification of 400.
Quantification of mRNA levels of types I and III
collagen. The amount of collagen mRNA in the LV was
determined by real-time quantitative polymerase chain re-
action with the Prism 7700 Sequence Detector (Perkin-
Elmer Corp., Foster, California), as previously described
(6,11). The sequences of all oligonucleotides used for type I
collagen mRNA were TGCTGCTTGCAGTAACGTCG
as the forward primer, TCAACACCATCTCTGCCTCG
as the reverse primer and ACTGGAGACAGAGGAC-
CGCGTGGAC as the detection probe. The sequences of
all oligonucleotides used for type III collagen mRNA were
TGCCCACAGCCTTCTACACCT as the forward
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primer, CAGCCATTCCTCCCACTCCAG as the re-
verse primer and CTCCTGTGCTTCCTGATGGC-
CATGGACC as the detection probe.
To correct the efficiency of complementary deoxyribonu-
cleic acid synthesis, the amounts of each measured mRNA
were divided by the amounts of glyceraldehyde-3-phosphate
dehydrogenase mRNA used as internal standards. Each
mRNA preparation was measured in at least three individ-
ual experiments.
Statistics. The results are expressed as the mean value 
SEM. The statistical analysis was conducted with a com-
mercially available statistical software program (Statview
version 5.0, SAS Institute, Cary, North Carolina). The
differences at specific stages among the groups were assessed
using one-way analysis of variance and the Fisher protected
least significant difference test. Bivariate correlations be-
tween variables were assessed by simple least-squares linear
regression analysis. A probability value 0.05 was consid-
ered statistically significant.
RESULTS
Hemodynamic effect of amlodipine administration. Sys-
tolic BP was significantly higher in the DHF rats at 13
weeks than in the control rats and thereafter (Fig. 1). At 19
weeks, LV end-diastolic pressure and the ratio of lung
weight to body weight were greater in the DHF rats than in
the control rats, indicating the presence of CHF in DHF
rats (Table 1). Echocardiographically determined posterior
wall thickness and LV mass index were greater in the DHF
rats than in the control rats, but there was no significant
difference in the LV end-diastolic dimension or mid-wall
fractional shortening. Left ventricular systolic function, as
assessed with mid-wall fractional shortening, was preserved
in DHF rats; however, tau was prolonged and MSC was
increased in the DHF rats as compared with control rats.
Elevation of systolic BP was suppressed in the HDA
group at 13 weeks and thereafter, but not in the LDA
group, and there was no difference in systolic BP between
the DHF and LDA groups (Fig. 1). The LV mass index
Figure 1. Serial changes in systolic blood pressure in the control, diastolic heart failure (DHF), high-dose amlodipine (administered amlodipine of high
dose [HDA]) and low-dose amlodipine (administered amlodipine of low dose [LDA]) rats. Data were obtained at the ages of 7, 13, 15, 17 and 19 weeks.
Data are presented as the mean value  SEM. *p  0.05 vs. control group; #p  0.05 vs. DHF group; †p  0.05 vs. high-dose amlodipine group at the
same point.
Table 1. Hemodynamic and Structural Characteristics of Each Group at 19 Weeks
Control
Group
(n  6)
DHF
Group
(n  8)
HDA
Group
(n  8)
LDA
Group
(n  7)
LV end-diastolic dimension (mm) 8.9  0.2 8.4  0.4 7.7  0.3* 8.8  0.4†
LV posterior wall thickness at end-diastole (mm) 1.3  0.1 2.3  0.2* 1.9  0.1* 1.9  0.1*
LV fractional shortening (%) 33  2 38  4 44  4*‡ 36  2†
Mid-wall fractional shortening (%) 18  1.5 16  0.9 19  0.8 16  0.3
LV end-diastolic pressure (mm Hg) 8  1 15  2* 7  1‡ 7  1‡
Tau (ms) 19  1 27  2* 18  2‡ 28  3*†
Mean MSC 1.8  0.1 2.5  0.1* 2.1  0.1*‡ 2.1  0.1*‡
LV mass index (mg/g) 2.0  0.1 3.7  0.1* 2.5  0.1*‡ 3.3  0.2*†
Lung weight/body weight (mg/g) 3.3  0.1 8.8  1.5* 3.5  0.1‡ 4.4  0.4‡
*p  0.05 versus control group. †p  0.05 versus HDA group. ‡p  0.05 versus DHF group. Data are expressed as the mean value  SEM.
DHF diastolic heart failure; HDA high-dose amlodipine; LDA low-dose amlodipine; LV left ventricular; MSCmyocardial stiffness constant; tau time constant
of isovolumic LV pressure fall.
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and LV end-diastolic dimension decreased at 19 weeks in
the HDA group as compared with the DHF group, but the
decrease in LV mass was not observed in the LDA group
(Table 1). Long-term amlodipine administration did not
affect mid-wall fractional shortening. In the HDA group,
tau was shorter and MSC was smaller than those values in
the DHF group. In the LDA group, tau was not shortened,
but there was a decrease in MSC, as compared with the
DHF group. Left ventricular end-diastolic pressure and the
ratio of lung weight to body weight were normal in both the
HDA and LDA groups, suggesting a prevention of CHF in
the HDA and LDA groups.
LV fibrotic change and myocardial stiffness. When the
hydroxyproline content in the LV was compared among the
groups, it was greater in the HDA and LDA groups than in
the control group, and the values were similar to those of the
DHF group (Fig. 2). The mRNA levels of types I and III
collagen were greater in the DHF group than in the control
group. The mRNA level of type I collagen was reduced, but
was still beyond the control value, and that of type III
collagen was not reduced in both the HDA or LDA group.
Figure 3 illustrates immunoreactive fibrillar type I collagen
protein deposition in the LV sections. An increase in type I
collagen was observed in the DHF rat as compared with the
control rat. A visible reduction in the level of type I collagen
was noted in the order of the control, HDA and LDA rats
(Fig. 3). In contrast, immunohistochemical staining of type
III collagen did not appear different among DHF, AMH
and AML rats.
The ratio of type I to type III collagen mRNA levels was
increased by fourfold in the DHF group as compared with
the control group (Fig. 2). Although amlodipine adminis-
tration did not decrease the hydroxyproline content, it
decreased the ratio of type I to type III collagen mRNA, and
its ratio was similar to that of the control group. In pooled
data taken from all 22 rats, there was a weak correlation
between MSC and the hydroxyproline content (r  0.479,
p  0.05), and MSC correlated better with the ratio of type
I to type III collagen mRNA levels (r  0.856, p  0.0001)
(Fig 2).
DISCUSSION
Long-term administration of amlodipine prevented the
elevation of LV end-diastolic pressure and the transition to
overt DHF in a hypertensive heart model. Such preventive
effects were not provided through LV systolic function and
were different with the doses of administration. High-dose
Figure 2. Hydroxyproline content of the left venticle (Pro-OH) and the ratio of type I to type III collagen mRNA levels (collagen I/III ratio) in the control,
diastolic heart failure (DHF), high-dose amlodipine (administered amlodipine of high dose [HDA]) and low-dose amlodipine (administered amlodipine
of low dose [LDA]) groups in the heart failure stage at 19 weeks (upper). *p  0.05 vs. control group; #p  0.05 vs. DHF group. The correlation between
myocardial stiffness constant (MSC) and Pro-OH or the collagen I/III ratio was determined in pooled data taken from all of the rats (n  22) (lower).
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(10 mg/kg/day) administration showed an antihypertensive
effect. Although this antihypertensive effect was not enough
to normalize the BP to the level of the control group, it
preserved systolic function and prevented diastolic dysfunc-
tion without suppressing compensatory or early hypertro-
phy. At this dose, amlodipine administration prevented
DHF mainly by suppressing BP and excessive hypertrophy.
Low-dose (1 mg/kg/day) administration, which was a sub-
deppessor dose, did not prevent progression of LV hyper-
trophy. It did not improve a reference of LV relaxation, tau,
but significantly decreased MSC. Thus, improvement of
myocardial stiffness obtained by a subdeppessor dose of
amlodipine was likely to contribute to the prevention of
DHF.
Although amlodipine administration did not alter the
hydroxyproline content, it normalized the ratio of type I to
type III collagen mRNA levels, which were significantly
increased in the DHF group as compared with the control
group. The MSC was correlated with the hydroxyproline
content, and a better correlation was obtained between
MSC and the ratio of type I to type III collagen mRNA
levels. Thus, myocardial stiffening was likely related to a
phenotype shift of collagen rather than to the collagen
content, and amlodipine was effective in the prevention of
collagen remodeling and of the transition to DHF.
Preventive effect of DHF by amlodipine administration.
In this study, high-dose administration of amlodipine de-
creased BP and LV end-diastolic pressure. The afterload
and preload reductions may contribute to the prevention of
excessive hypertrophy and, hence, the transition to DHF.
Short-acting calcium antagonists, such as verapamil, dil-
tiazem and nifedipine, have shown potentially unfavorable
effects, and the reason for these effects has been considered
as negative inotropic effects, reflex activation of the
sympathetic nervous system and activation of the rennin-
angiotensin system (1,12). In contrast, Abernethy et al. (13)
showed that the increase in plasma levels of norepinephrine,
epinephrine, renin and aldosterone could be prevented with
amlodipine treatment. Lund-Johansen et al. (14) showed an
increase in plasma norepinephrine levels in patients with
nifedipine-treated essential hypertension, but not in
amlodipine-treated patients. Thus, the long-acting calcium
antagonist amlodipine may avoid abnormal activation of the
rennin-angiotensin system and reflex stimulation of the
sympathetic nervous system. In our previous study (15),
administration of a subdeppressor dose of the angiotensin II
Figure 3. Immunohistochemical staining of the myocardium from a Dahl-SS rat with type I collagen in the LV (control rat, upper left), an untreated rat
(diastolic heart failure [DHF], upper right) and a rat treated with high-dose amlodipine ( administered amlodipine of high dose [HDA], lower left)
and low-dose amlodipine (administered amlodipine of low dose [LDA]) at 19 weeks. An increase in type I collagen was observed in the DHF rat as
compared with the control rat. A visible reduction in the level of type I collagen was noted in the order of the control, high-dose amlodipine and low-dose
amlodipine rats.
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type 1 receptor antagonist, candesartan cilexetil, did not
suppress the initial development of LV hypertrophy in
hypertensive rats; however, the transition to DHF was
suppressed by prevention of further progressive hypertrophy
and fibrosis. Thus, we believe excessive hypertrophy plays an
important role in the development of DHF, and that this
type of hypertrophy is dependent on the rennin-angiotensin
system. In the present study, administration of HDA
prevented the development of excessive hypertrophy and,
hence, DHF. This effect may be at least partly related to
inactivation of the rennin-angiotensin system. The preven-
tive effects of LDA, however, cannot be explained in the
same way as those of HDA, because LV excessive hyper-
trophy was not prevented by the use of LDA.
Myocardial fibrosis and MSC. A weak but significant
correlation between MSC and the hydroxyproline content
of the LV indicates an inter-relationship between myocar-
dial stiffening and myocardial fibrosis in our model of DHF.
Brilla et al. (16) demonstrated a close relationship between
myocardial fibrosis and myocardial diastolic stiffness in
spontaneously hypertensive rats that had heart failure due to
systolic dysfunction. The results of the current study also
emphasize the crucial role of myocardial fibrosis in the
induction of myocardial stiffening and DHF. However, the
correlation coefficient between the collagen content and
MSC was not high in this study, and factors other than the
collagen content may also contribute to myocardial stiffen-
ing.
Phenotype shift of collagen and MSC. There are at least
six phenotypes of collagen (17,18), and types I and III
collagen are essential components of the myocardial ECM
(19,20). Type I collagen production was more upregulated
than type III collagen production in DHF rats. The change
in the regulation of collagen production was associated with
a similar change in the protein level, as evidenced by
immunohistochemical findings. Types I and III collagen
play different roles in maintaining myocardial structural and
functional integrity: type I collagen mainly exerts rigidity,
whereas type III collagen contributes to elasticity (21–23).
Thus, the increase in the ratio of type I to type III collagen
may well exacerbate myocardial stiffness. Previous animal
and human studies have reported a phenotype shift of
collagen in systolic heart failure (24–26). Weber et al. (27)
showed that the phenotype shift was likely responsible for
systolic dysfunction. However, both systolic and diastolic
functions are impaired in the presence of systolic heart
failure and are closely related with each other. The present
study has expanded the findings of previous studies by
demonstrating a close relationship between a phenotype
shift of collagen and myocardial stiffening, as well as the
crucial role of a phenotype shift in DHF.
Amlodipine and fibrosis. Although LDA did not prevent
the development of excessive hypertrophy, it reduced MSC
and prevented elevation of LV end-diastolic pressure, as
well as development of DHF, without a decrease in the
myocardial collagen content. Yamazaki et al. (28) showed
that amlodipine administration strongly reduced type I
collagen gene expression in spontaneously hypertensive rats.
In the present study, the decrease in type I collagen
expression was also observed in the amlodipine-treated
groups. Amlodipine administration reduced the ratio of type
I to type III collagen, which may likely account for the
decrease in MSC and, hence, the prevention of DHF. Thus,
the inhibition of a phenotype shift of collagen by amlodip-
ine administration may play an important role in the
prevention of DHF achieved by LDA. Most recently,
PRAISE II failed to demonstrate any beneficial effects of
long-term amlodipine administration on the total mortality
of patients with nonischemic cardiomyopathy with LV
systolic dysfunction; however, our results suggest beneficial
effects of amlodipine in patients with DHF that shows
pathophysiologic findings different from those of systolic
heart failure (6,29).
Study limitations. There are several limitations of this
study. First, myocardial stiffening may well be affected by
alterations in the three-dimensional structure of the ECM,
such as struts, weave and strands (22), changes in myocar-
dial cross linking (27,30), myocardial ischemia and edema
and coronary engorgement. The current study did not assess
these changes, and future studies are necessary. However, a
close correlation was observed between a phenotype shift of
collagen and myocardial stiffness, and a lack of such data
may not weaken our conclusions. It is not clarified in the
current study whether the calcium antagonist directly affects
collagen synthesis or degradation, or both, or exerts its
effects indirectly through modulating other neurohumoral
systems, such as the renin-angiotensin-aldosterone system.
This should be clarified in future studies.
Second, MSC was calculated only in the septum and
posterior wall. This is because MSC was determined with
LV M-mode echocardiography. However, LV hypertrophy
in our rats was symmetrical, and the difference in MSC
between the septum and posterior wall was certainly small.
Conclusions. Myocardial stiffening is facilitated by a phe-
notype shift from type III to type I collagen in the LV,
rather than by an increase in the collagen content in
hypertensive hearts. Thus, not only the reduction in the
collagen content, but also the prevention of the phenotype
shift should be a target for therapy of DHF, and amlodipine
may exert its beneficial effects through amelioration of
collagen remodeling in the treatment of DHF.
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